Spotlight
Topic
Brand Insights
Subscribe
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
AZ in Asthma Deal with New Zealand Firm
July 23, 2015.
AstraZeneca (AZ) has entered a long term partnership with New Zealand's Adherium (NZ) Limited. The deal is described by AZ as a "world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions". Adherium will supply innovative new devices and sensors that AstraZeneca will incorporate within global patient support programs for patients with COPD and asthma. Fewer than 50% of asthma patients adhere to their prescribed preventative medications. The addition of an Adherium Smartinhaler is said to increase adherence by up to 59% in adults and 180% in children with asthma.
Recent Videos
Related Content
